Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions

被引:16
作者
Maria Grazia Clemente [1 ]
Claudia Mandato [2 ]
Marco Poeta [3 ]
Pietro Vajro [3 ,4 ]
机构
[1] ediatric Clinic, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari
[2] Pediatrics of AORN Santobono-Pausilipon  3. Pediatrics, Department of Medicine, Surgery and Dentistry - “Scuola Medica Salernitana”, University of Salerno 
关键词
Non-alcoholic fatty liver disease; Childhood obesity; Non-alcoholic steatohepatitis; Hepatic metabolic syndrome; Non-alcoholic fatty liver disease diagnosis;
D O I
暂无
中图分类号
R725.7 [小儿消化系及腹部疾病];
学科分类号
100202 ;
摘要
Non-alcoholic fatty liver disease(NAFLD) in children is becoming a major health concern. A "multiple-hit" pathogenetic model has been suggested to explain the progressive liver damage that occurs among children with NAFLD. In addition to the accumulation of fat in the liver, insulin resistance(IR) and oxidative stress due to genetic/epigenetic background, unfavorable lifestyles, gut microbiota and gut-liver axis dysfunction, and perturbations of trace element homeostasis have been shown to be critical for disease progression and the development of more severe inflammatory and fibrotic stages [non-alcoholic steatohepatitis(NASH)]. Simple clinical and laboratory parameters, such as age, history, anthropometrical data(BMI and waist circumference percentiles), blood pressure, surrogate clinical markers of IR(acanthosis nigricans), abdominal ultrasounds, and serum transaminases, lipids and glucose/insulin profiles, allow a clinician to identify children with obesity and obesity-related conditions, including NAFLD and cardiovascular and metabolic risks. A liver biopsy(the "imperfect" gold standard) is required for a definitive NAFLD/NASH diagnosis, particularly to exclude other treatable conditions or when advanced liver disease is expected on clinical and laboratory grounds and preferably prior to any controlled trial of pharmacological/surgical treatments. However, a biopsy clearly cannot represent a screening procedure. Advancements in diagnostic serum and imaging tools, especially for the non-invasive differentiation between NAFLD and NASH, have shown promising results, e.g., magnetic resonance elastography. Weight loss and physical activity should be the first option of intervention.Effective pharmacological treatments are still under development; however, drugs targeting IR, oxidative stress, proinflammatory pathways, dyslipidemia, gut microbiota and gut liver axis dysfunction are an option for patients who are unable to comply with the recommended lifestyle changes. When morbid obesity prevails, bariatric surgery should be considered.
引用
收藏
页码:8078 / 8093
页数:16
相关论文
共 69 条
[1]   Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future [J].
Mehran Rahimlou ;
Hoda Ahmadnia ;
Azita Hekmatdoost .
World Journal of Hepatology, 2015, 7 (25) :2597-2602
[2]   Early probiotics to prevent childhood metabolic syndrome: A systematic review [J].
Haribalakrishna Balasubramanian ;
Sanjay Patole .
World Journal of Methodology, 2015, (03) :157-163
[3]   Understanding the pathophysiological mechanisms in the pediatric non-alcoholic fatty liver disease: The role of genetics [J].
Pierluigi Marzuillo ;
Anna Grandone ;
Laura Perrone ;
Emanuele Miraglia del Giudice .
World Journal of Hepatology, 2015, (11) :1439-1443
[4]  
Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease[J]. Mustafa Koplay,Mesut Sivri,Hasan Erdogan,Alaaddin Nayman.World Journal of Hepatology. 2015(05)
[5]  
Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease[J]. Shao-Ren Zhang,Xiao-Ming Fan.World Journal of Gastroenterology. 2015(11)
[6]  
Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease[J]. Lucia Pacifico,Enea Bonci,Lidia Marandola,Sara Romaggioli,Stefano Bascetta,Claudio Chiesa.World Journal of Gastroenterology. 2014(45)
[7]   Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease [J].
Giulia Paolella ;
Claudia Mandato ;
Luca Pierri ;
Marco Poeta ;
Martina Di Stasi ;
Pietro Vajro .
World Journal of Gastroenterology, 2014, 20 (42) :15518-15531
[8]  
Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease[J]. Jiao-Ya Xu,Zhong-Ping Li,Li Zhang,Guang Ji.World Journal of Gastroenterology. 2014(37)
[9]   Noninvasive biomarkers in non-alcoholic fatty liver disease:Current status and a glimpse of the future [J].
Emer Fitzpatrick ;
Anil Dhawan .
World Journal of Gastroenterology, 2014, (31) :10851-10863
[10]   Effects of probiotics on nonalcoholic fatty liver disease:A meta-analysis [J].
Yan-Yan Ma ;
Lin Li ;
Chao-Hui Yu ;
Zhe Shen ;
Li-Hua Chen ;
You-Ming Li .
World Journal of Gastroenterology, 2013, (40) :6911-6918